Full Breakdown
Food and Drug Administration (FDA) Advisory Panels Face Potential Pharma Influence via Patient Representatives
By Drooid · · How we work
Core Findings of the Study
A 10-year review of 12 FDA advisory committees covering 240 voting meetings between 2013 and 2022 found that nearly 40 percent of those meetings included at least one patient or consumer representative linked to an advocacy organization funded by drug, device, or biotechnology companies. In 11 percent of meetings, the representative’s organization received money from the very drugmaker whose product was under review. The study, published in *Health Affairs Scholar* and conducted by researchers at the USC Schaeffer Center for Health Policy & Economics, notes that these ties were often undisclosed.
Scope and Context of Advisory Committees
FDA advisory committees provide non-binding recommendations on drug and device approvals and are composed primarily of external scientists. They also routinely include patient and consumer representatives to convey public perspectives. While the agency has well-established conflict-of-interest rules for scientific experts, it has paid less attention to potential conflicts among the lay representatives.
Data Highlights
- Overall presence: ? 40 % of meetings featured a tied patient or consumer rep.
- Direct product funding: 11 % of meetings involved a rep whose organization was funded by the product’s sponsor.
- Therapeutic-area concentrations:
- Nervous-system drug panels – 89 % of meetings with tied consumer reps
- Gastrointestinal drug panels – 67 %
- Cardiovascular and renal drug panels – 61 % (the highest overall share)
- Arthritis panel – 53 % (the panel was discontinued in 2025)
Official Responses and Policy Gaps
The FDA’s 2016 draft guidance requires disclosure of financial relationships that could appear to create a conflict, but the study indicates many affiliations remain undisclosed because the forms used by committee members do not emphasize such ties. Moreover, there is currently no mechanism for publicly reporting disclosed relationships, limiting external scrutiny.
Verbatim Quotes
- “Given how dependent some patient organizations are on industry support, it’s reasonable to question whether these relationships may affect how patient representatives vote,” — Genevieve Kanter, said lead author — Genevieve Kanter, lead author and associate professor at the USC Schaeffer Center for Health Policy & Economics.
